In vivo imaging assay for the convenient evaluation of antiviral compounds against cytomegalovirus in mice.
Evaluation of newly identified antiviral compounds against cytomegalovirus (CMV) in vivo still requires laborious and time-consuming experiments using a large number of animals. In this study, we examined an in vivo imaging assay for the evaluation of antiviral compounds using a recombinant murine CMV expressing EGFP (MCMV-GFP). We found the followings: (1) Fluorescent signals were detectable from 1 day after subcutaneous inoculation of the viruses into the backs of mice, and reached to the peak within 2-4 days. (2) Incubation period required for the signal appearance and peak signal intensities depended on the inoculated dose. (3) Not only BALB/c but also a hairless mouse strain, HR1, can be used for the assay, and no need to shave the HR1 mice added to the convenience of the assay. (4) However, BALB/c mice showed better sensitivity and dose-response to the inoculated virus, and inoculation with 200 PFUs of MCMV-GFP still yielded the signals. (5) Demonstration of the antiviral effect of ganciclovir provided a proof-of-concept. Thus, the in vivo imaging assay can allow the fast and convenient initial evaluation of anti-CMV candidate compounds in animals prior to comprehensive analyses.